Search

everythinglearnresearchcommunity

for

Search:↓

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

CS12192 effectively treats alopecia areata with better safety than current options.

The treatment combination is effective and generally safe for lung cancer.

JAK inhibitors effectively treat skin conditions and topical forms are safer.

Tofacitinib may help treat hair loss in children with alopecia areata.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Ruxolitinib can cause a delayed skin reaction on the nose.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.

Deucravacitinib helped a man regrow hair significantly.

The FDA approved a new Pfizer drug for hair loss in teens.

These new skin treatments are safer and more effective with minimal side effects.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.